PCSK9 and atherosclerosis: The FOURIER trial (n=27,564) on individuals with atherosclerosis and advanced CKD demonstrated greater reduction in the composite of CV death, MI, and stroke with evolocumab (PCSK9 inhibitor) treatment [84].